Rep. Kevin Hern Sells Shares of Organon & Co. (NYSE:OGN)

Key Points

• Rep. Kevin Hern sold $1,001–$15,000 of Organon & Co. shares on August 5 through the Hern Family Foundation account, alongside similarly sized sales in six other companies.
• Organon stock opened at $13.65, near its 52-week high of $13.66, and was up 0.3%. The company declared a quarterly dividend of $0.02 per share, implying a 0.6% annual yield.
• Analyst sentiment remains cautious: five analysts rate the stock Hold and two rate it Sell, producing a MarketBeat consensus of “Reduce” and an average price target of $11.40.

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Organon & Co. NYSE: OGN. In a filing disclosed on August 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Organon & Co. stock on August 5th. The trade occurred in the Representative's "HERN FAMILY FOUNDATION" account.

Representative Kevin Hern also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Diageo NYSE: DEO on 8/5/2026.
• Sold $1,001 - $15,000 in shares of Estee Lauder Companies NYSE: EL on 8/5/2026.
• Sold $1,001 - $15,000 in shares of Mondelez International NASDAQ: MDLZ on 8/5/2026.
• Sold $1,001 - $15,000 in shares of Versant NASDAQ: VSNT on 8/5/2026.
• Sold $1,001 - $15,000 in shares of Comcast NASDAQ: CMCSA on 8/5/2026.
• Sold $1,001 - $15,000 in shares of Kenvue NYSE: KVUE on 8/5/2026.

Organon & Co. Stock Up 0.3%

Organon & Co. stock opened at $13.65 on Wednesday. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.66. The business has a fifty day moving average price of $13.50 and a 200-day moving average price of $10.65. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44. The stock has a market capitalization of $3.59 billion, a price-to-earnings ratio of 17.73, a PEG ratio of 1.26 and a beta of 1.55.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Organon & Co.'s dividend payout ratio is currently 10.39%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Weiss Ratings downgraded Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 3rd. BNP Paribas Exane restated a "neutral" rating and set a $14.00 price objective (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Piper Sandler raised shares of Organon & Co. from an "underweight" rating to a "neutral" rating and increased their price objective for the company from $5.00 to $14.00 in a research report on Tuesday, April 28th. Finally, Zacks Research upgraded shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 14th. Five investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Reduce" and an average target price of $11.40.

Institutional Investors Weigh In On Organon & Co.

A number of institutional investors and hedge funds have recently modified their holdings of the company. Handelsbanken Fonder AB boosted its position in Organon & Co. by 24.8% in the second quarter. Handelsbanken Fonder AB now owns 113,800 shares of the company's stock valued at $1,541,000 after buying an additional 22,600 shares during the last quarter. Allied Private Wealth LLC purchased a new position in Organon & Co. during the 2nd quarter worth approximately $33,000. GAMMA Investing LLC lifted its stake in Organon & Co. by 69.8% during the 2nd quarter. GAMMA Investing LLC now owns 5,782 shares of the company's stock valued at $78,000 after acquiring an additional 2,376 shares during the period. WNY Asset Management LLC acquired a new stake in Organon & Co. during the 1st quarter valued at approximately $64,000. Finally, Orographic Financial Advisors LLC acquired a new stake in Organon & Co. during the 1st quarter valued at approximately $1,522,000. Institutional investors and hedge funds own 77.43% of the company's stock.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma's 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027. Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma's 1st Congressional District. He declared candidacy for the 2026 election. Kevin Hern went into business as a McDonald's franchisee in 1999. He acquired 10 McDonald's franchises by 2012. He served on the McDonald's National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source